Trifecta Capital Advisors, LLC Bristol Myers Squibb CO Transaction History

Trifecta Capital Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 16, 2024	SELL	$47.98 - $54.4 $1,679 - $1,904	-35 Reduced 37.23%	59 $3.2 Million
Q4 2023 Jan 25, 2024	SELL	$48.48 - $57.85 $1.68 Million - $2.01 Million	-34,751 Reduced 99.73%	94 $4.82 Million
Q3 2023 Nov 01, 2023	SELL	$57.89 - $64.73 $131,815 - $147,390	-2,277 Reduced 6.13%	34,845 $2.02 Billion
Q2 2023 Aug 14, 2023	BUY	$63.71 - $70.74 $213,428 - $236,978	3,350 Added 9.92%	37,122 $2.37 Billion
Q1 2023 May 09, 2023	BUY	$65.71 - $74.53 $44,025 - $49,935	670 Added 2.02%	33,772 $2.34 Billion
Q4 2022 Jan 17, 2023	BUY	$68.48 - $81.09 $2.27 Million - $2.68 Million	33,102 New	33,102 $2.38 Billion

2,512

1.47B

30.4M

30.9M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Trifecta Capital Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Trifecta Capital Advisors, LLC with notifications on news.